Addex completes ads ratio change

Ad hoc announcement pursuant to art. 53 lr geneva, switzerland, october 20, 2023 - addex therapeutics (six and nasdaq: adxn), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that the company's previously disclosed change to its american depositary shares (“adss”) to ordinary share ratio has been accepted by nasdaq and will be effective on october 23, 2023.
ADXN Ratings Summary
ADXN Quant Ranking